IL286967A - Methods of depleting disease causing agents via antibody targeted phagocytosis - Google Patents

Methods of depleting disease causing agents via antibody targeted phagocytosis

Info

Publication number
IL286967A
IL286967A IL286967A IL28696721A IL286967A IL 286967 A IL286967 A IL 286967A IL 286967 A IL286967 A IL 286967A IL 28696721 A IL28696721 A IL 28696721A IL 286967 A IL286967 A IL 286967A
Authority
IL
Israel
Prior art keywords
engulfment
emptying
antibody
targeted
disease
Prior art date
Application number
IL286967A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dren Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dren Bio Inc filed Critical Dren Bio Inc
Publication of IL286967A publication Critical patent/IL286967A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL286967A 2019-04-05 2021-10-04 Methods of depleting disease causing agents via antibody targeted phagocytosis IL286967A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Publications (1)

Publication Number Publication Date
IL286967A true IL286967A (en) 2021-12-01

Family

ID=72667025

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286967A IL286967A (en) 2019-04-05 2021-10-04 Methods of depleting disease causing agents via antibody targeted phagocytosis

Country Status (12)

Country Link
US (2) US20220169737A1 (enExample)
EP (1) EP3947467A4 (enExample)
JP (2) JP2022527646A (enExample)
KR (1) KR20220031995A (enExample)
CN (1) CN114502585A (enExample)
AU (1) AU2020253621A1 (enExample)
BR (1) BR112021019950A2 (enExample)
CA (1) CA3136272A1 (enExample)
IL (1) IL286967A (enExample)
MX (1) MX2021012035A (enExample)
SG (1) SG11202110663UA (enExample)
WO (1) WO2020206354A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2021222894A1 (en) 2020-05-01 2021-11-04 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibodies
MX2023004054A (es) 2020-10-07 2023-06-29 Dren Bio Inc Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
CN119301156A (zh) * 2022-04-04 2025-01-10 德伦生物公司 抗Dectin-1抗体和其使用方法
US20250223364A1 (en) * 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
KR20260048578A (ko) * 2023-07-31 2026-04-10 드렌 바이오 매니지먼트, 인크. Dectin-1 및 TROP-2에 결합하는 다중특이적 결합 단백질 및 이의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679949B (zh) * 2007-02-23 2015-08-19 贝勒研究院 通过dectin-1激活人抗原呈递细胞的治疗性应用
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
US12384850B2 (en) * 2017-06-25 2025-08-12 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
CA3106796A1 (en) * 2018-07-19 2020-01-23 Oncohost Ltd Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer
EA202190183A1 (ru) * 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения

Also Published As

Publication number Publication date
US20250206826A1 (en) 2025-06-26
BR112021019950A2 (pt) 2021-12-07
US20220169737A1 (en) 2022-06-02
SG11202110663UA (en) 2021-10-28
JP2022527646A (ja) 2022-06-02
MX2021012035A (es) 2022-03-11
AU2020253621A1 (en) 2021-11-11
CA3136272A1 (en) 2020-10-08
CN114502585A (zh) 2022-05-13
EP3947467A4 (en) 2023-01-04
KR20220031995A (ko) 2022-03-15
JP2025096316A (ja) 2025-06-26
WO2020206354A1 (en) 2020-10-08
EP3947467A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL281059A (en) Methods of making chimeric antigen receptor-expressing cells
SG11202106214YA (en) Novel anti-ccr8 antibody
SI3843757T1 (sl) Kriopreservirane NK-celice, predhodno obložene s konstruktom protiteles
EP3440191A4 (en) CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS
CL2020000877S1 (es) Envase.
CL2020001711S1 (es) Envase.
IL276626A (en) Formulations of B7-H4 antibody
CL2020000878S1 (es) Envase.
EP4081547A4 (en) Novel anti-fgfr2b antibodies
CL2020000649S1 (es) Envase.
EP4049941C0 (en) CONTAINER-BEARING DEVICE
CL2020001712S1 (es) Envase.
CL2020001710S1 (es) Envase.
IL282214A (en) Container-manoeuvring apparatus
CL2020000652S1 (es) Envase.
CL2020001714S1 (es) Envase.
CL2020000876S1 (es) Envase.
CL2020000881S1 (es) Envase.
EP4081539A4 (en) Novel anti-fgfr2b antibodies
IL280367A (en) CD226 agonist antibodies
CL2020000648S1 (es) Envase.
IL279865A (en) A new stable high concentration formulation for anti-FXIa antibodies
CL2020000650S1 (es) Envase.
EP4062933A4 (en) Antibody-containing preparation
EP3567101A4 (en) NATURAL KILLER CELL EXPRESSING AN ANTI-COTININ CHEMERIC ANTIGEN RECEPTOR